Acetamide

Acetamide

SCHEMBL5790939

CC(N)=O.Nc1ncc[nH]c1=O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GDA Q9Y2T3 1/20 0.37
CSNK1A1 P48729 1/20 0.37
TYRO3 Q06418 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 2/20 0.33
MAPT P10636 1/20 0.33
NAPRT Q6XQN6 1/20 0.32
AURKA O14965 1/20 0.32
AURKB Q96GD4 1/20 0.32
INCENP Q9NQS7 1/20 0.32
GRIA1 P42261 1/20 0.32
GRIA2 P42262 1/20 0.32
GRIA3 P42263 1/20 0.32
GRIA4 P48058 1/20 0.32
FDPS P14324 1/20 0.32
GCK P35557 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL392829 0.88
SCHEMBL2490454 0.72 CSNK1A1 (0.42) GDACSNK1A1TYRO3DYRK1BALDH1A1
SCHEMBL2785935 0.71 KLK1 (0.36) GDACSNK1A1TYRO3DYRK1BALDH1A1
Acetamide SCHEMBL28781848 0.71 CSNK1A1 (0.38) GDACSNK1A1TYRO3DYRK1BALDH1A1
Urea SCHEMBL28133713 0.68 NPC1 (0.49) CSNK1A1TYRO3DYRK1BALDH1A1SMN1; SMN2
SCHEMBL13022785 0.68 CSNK1A1 (0.35) CSNK1A1TYRO3DYRK1BALDH1A1SMN1; SMN2
SCHEMBL27778080 0.68 NPC1 (0.38) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
Azomycin SCHEMBL6349407 0.68 ALDH1A1 (0.39) CSNK1A1TYRO3DYRK1BALDH1A1SMN1; SMN2
SCHEMBL7556283 0.68 GDA (0.40) GDAALDH1A1SMN1; SMN2NPC1RAB9A
Ethane SCHEMBL923419 0.67 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006009696-A2 ANTICOAGULANT CONTRAST MEDIA HEMATROPE PHARMACEUTICALS INC (US) 2006-01-26 WO disclosed
US-20050281746-A1 Anticoagulant contrast media HEMATROPE PHARMACEUTICALS, INC. 2005-12-22 US disclosed
US-20030045679-A1 Calcineurin modulators ALBANY MEDICAL COLLEGE 2003-03-06 US disclosed
WO-2003006619-A2 CALCINEURIN MODULATORS CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC (US) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050281746-A1 Anticoagulant contrast media SERPINC1, F2, TFPI GDA 2102/4885CSNK1A1 4668/4885TYRO3 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.